Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3895MR)

This product GTTS-WQ3895MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens; Chimeric
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3895MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2273MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ALXN1007
GTTS-WQ9307MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMP-321
GTTS-WQ2519MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 334
GTTS-WQ9391MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ7153MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA FG-3019
GTTS-WQ14886MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ9063MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMC-A12
GTTS-WQ13719MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RC48-0
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW